• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fareva, ApiJect ink 10-year licensing agreement on fill-finish production lines

December 9, 2021 By Sean Whooley

ApijectFareva and ApiJect Systems today announced a licensing agreement to fill-finish more than 500 million injectable drug doses per year.

Under the agreement, Fareva intends to invest more than $56.5 million to install three blow-fill-seal production lines with support from the Government of France through the France Relance industry initiative, as well as the Investments for the Future Program (PIA).

When operational, the companies expect the manufacturing lines to fill-finish more than 500 doses per year of vaccines and other large-molecule injectable drugs using ApiJect’s prefilled injector technology, according to a news release.

The new lines will be stationed in Fareva Exelvision in Annonay, France. Machines will be purchased from Rommelag in Germany. The companies intend to start the first validation batches in June 2022, while the capacity expands ApiJect’s licensing of its manufacturing and device technology to the U.S. and Europe.

ApiJect said its blow-fill-seal (BFS) aseptic packaging process can package certain vaccines and large-molecule formulations successfully, while the company looks to expand BFS’ capabilities to additional drug products, including temperature-sensitive pharmaceuticals.

The company said that, once cleared by regulators, it will provide the necessary needle hub and other attachable components to convert finished BFS single-dose containers form the lines into easy-to-assemble, ready-to-use prefilled injectors.

“Our mission at ApiJect is to support and execute a strategy of expanded distributed fill-finish capacity in the U.S. and regionally around the world,” ApiJect CEO & Chair Jay Walker said in the release. “This is desperately needed in the battle against COVID, particularly as we continue to face emerging variants. Distributed fill-finish capacity will also yield huge dividends when future pandemics and other possible bio-emergencies threaten our populations. Fareva, along with its support from the French Government, is showing itself to be a vital leader in confronting and defeating the COVID threat.”

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: ApiJect Systems

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS